Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT01708538
Previous Study | Return to List | Next Study

The Effects of Corneal Collagen Cross-linking

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01708538
Recruitment Status : Recruiting
First Posted : October 17, 2012
Last Update Posted : March 10, 2021
Information provided by (Responsible Party):
Rush Eye Associates

Brief Summary:
The corneal collagen cross-linking treatment has been used with increasing success to treat corneal dystrophies such as "keratoconus." Recent advances have allowed different techniques for performing this cross-linking treatment. This study investigates the effects of corneal cross-linking using different surgical techniques.

Condition or disease Intervention/treatment Phase
Corneal Ectasia Disorders Including Keratoconus Drug: CXL Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques.
Study Start Date : October 2012
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022

Arm Intervention/treatment
Active Comparator: Epithelium on
Epi not removed during CXL treatment
Drug: CXL
corneal crosslinking

Active Comparator: Epithelium off
Epi removed before CXL treatment
Drug: CXL
corneal crosslinking

Primary Outcome Measures :
  1. Visual acuity [ Time Frame: 1 year ]
    Best corrected Snellen acuity

  2. Keratometry measurements [ Time Frame: 1 year ]
    Average curvature of the cornea

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion Criteria:

  • Unwilling or unable to participate in trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01708538

Layout table for location contacts
Contact: Sloan W Rush, MD 806-353-0125

Layout table for location information
United States, Texas
Rush Eye Associates Recruiting
Amarillo, Texas, United States, 79106
Contact: Sunday Fowler    806-353-0125      
Principal Investigator: Sloan W Rush, MD         
Sponsors and Collaborators
Rush Eye Associates
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Rush Eye Associates Identifier: NCT01708538    
Other Study ID Numbers: Rush CXL
First Posted: October 17, 2012    Key Record Dates
Last Update Posted: March 10, 2021
Last Verified: March 2021
Keywords provided by Rush Eye Associates:
keratoconus, corneal collagen crosslinking, riboflavin, corneal ectasia
Additional relevant MeSH terms:
Layout table for MeSH terms
Dilatation, Pathologic
Corneal Diseases
Eye Diseases
Pathological Conditions, Anatomical